116 related articles for article (PubMed ID: 28468914)
1. RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation.
Engel C; Brügmann G; Lambing S; Mühlenbeck LH; Marx S; Hagen C; Horváth D; Goldeck M; Ludwig J; Herzner AM; Drijfhout JW; Wenzel D; Coch C; Tüting T; Schlee M; Hornung V; Hartmann G; Van den Boorn JG
Cancer Immunol Res; 2017 Jun; 5(6):455-467. PubMed ID: 28468914
[TBL] [Abstract][Full Text] [Related]
2. Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity.
Thier B; Zhao F; Stupia S; Brüggemann A; Koch J; Schulze N; Horn S; Coch C; Hartmann G; Sucker A; Schadendorf D; Paschen A
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35697379
[TBL] [Abstract][Full Text] [Related]
3. Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells.
Daßler-Plenker J; Paschen A; Putschli B; Rattay S; Schmitz S; Goldeck M; Bartok E; Hartmann G; Coch C
Int J Cancer; 2019 Apr; 144(7):1645-1656. PubMed ID: 30230526
[TBL] [Abstract][Full Text] [Related]
4. Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy.
Jacobson ME; Wang-Bishop L; Becker KW; Wilson JT
Biomater Sci; 2019 Jan; 7(2):547-559. PubMed ID: 30379158
[TBL] [Abstract][Full Text] [Related]
5. RIG-I activation induces the release of extracellular vesicles with antitumor activity.
Daßler-Plenker J; Reiners KS; van den Boorn JG; Hansen HP; Putschli B; Barnert S; Schuberth-Wagner C; Schubert R; Tüting T; Hallek M; Schlee M; Hartmann G; Pogge von Strandmann E; Coch C
Oncoimmunology; 2016; 5(10):e1219827. PubMed ID: 27853642
[TBL] [Abstract][Full Text] [Related]
6. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
Heidegger S; Kreppel D; Bscheider M; Stritzke F; Nedelko T; Wintges A; Bek S; Fischer JC; Graalmann T; Kalinke U; Bassermann F; Haas T; Poeck H
EBioMedicine; 2019 Mar; 41():146-155. PubMed ID: 30852164
[TBL] [Abstract][Full Text] [Related]
7. Klotho deficiency intensifies hypoxia-induced expression of IFN-α/β through upregulation of RIG-I in kidneys.
Urabe A; Doi S; Nakashima A; Ike T; Morii K; Sasaki K; Doi T; Arihiro K; Masaki T
PLoS One; 2021; 16(10):e0258856. PubMed ID: 34673800
[TBL] [Abstract][Full Text] [Related]
8. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner.
Han Q; Zhang C; Zhang J; Tian Z
Hepatology; 2011 Oct; 54(4):1179-89. PubMed ID: 21721030
[TBL] [Abstract][Full Text] [Related]
9. Ascorbic acid, but not dehydroascorbic acid increases intracellular vitamin C content to decrease Hypoxia Inducible Factor -1 alpha activity and reduce malignant potential in human melanoma.
Fischer AP; Miles SL
Biomed Pharmacother; 2017 Feb; 86():502-513. PubMed ID: 28012930
[TBL] [Abstract][Full Text] [Related]
10. Endothelial RIG-I activation impairs endothelial function.
Asdonk T; Motz I; Werner N; Coch C; Barchet W; Hartmann G; Nickenig G; Zimmer S
Biochem Biophys Res Commun; 2012 Mar; 420(1):66-71. PubMed ID: 22402283
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy.
Wang-Bishop L; Wehbe M; Pastora LE; Yang J; Kimmel BR; Garland KM; Becker KW; Carson CS; Roth EW; Gibson-Corley KN; Ulkoski D; Krishnamurthy V; Fedorova O; Richmond A; Pyle AM; Wilson JT
ACS Nano; 2024 May; 18(18):11631-11643. PubMed ID: 38652829
[TBL] [Abstract][Full Text] [Related]
12. Redox control of retinoic acid receptor activity: a novel mechanism for retinoic acid resistance in melanoma cells.
Demary K; Wong L; Liou JS; Faller DV; Spanjaard RA
Endocrinology; 2001 Jun; 142(6):2600-5. PubMed ID: 11356710
[TBL] [Abstract][Full Text] [Related]
13. RIG-I activation is critical for responsiveness to checkpoint blockade.
Heidegger S; Wintges A; Stritzke F; Bek S; Steiger K; Koenig PA; Göttert S; Engleitner T; Öllinger R; Nedelko T; Fischer JC; Makarov V; Winter C; Rad R; van den Brink MRM; Ruland J; Bassermann F; Chan TA; Haas T; Poeck H
Sci Immunol; 2019 Sep; 4(39):. PubMed ID: 31519811
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer.
Ellermeier J; Wei J; Duewell P; Hoves S; Stieg MR; Adunka T; Noerenberg D; Anders HJ; Mayr D; Poeck H; Hartmann G; Endres S; Schnurr M
Cancer Res; 2013 Mar; 73(6):1709-20. PubMed ID: 23338611
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma.
Ma H; Jin S; Yang W; Zhou G; Zhao M; Fang S; Zhang Z; Hu J
Br J Cancer; 2018 Feb; 118(4):509-521. PubMed ID: 29348488
[TBL] [Abstract][Full Text] [Related]
16. RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma.
Lambing S; Tan YP; Vasileiadou P; Holdenrieder S; Müller P; Hagen C; Garbe S; Behrendt R; Schlee M; van den Boorn JG; Bartok E; Renn M; Hartmann G
J Mol Cell Biol; 2023 Jun; 15(1):. PubMed ID: 36626927
[TBL] [Abstract][Full Text] [Related]
17. Skin mild hypoxia enhances killing of UVB-damaged keratinocytes through reactive oxygen species-mediated apoptosis requiring Noxa and Bim.
Nys K; Maes H; Andrei G; Snoeck R; Garmyn M; Agostinis P
Free Radic Biol Med; 2012 Mar; 52(6):1111-20. PubMed ID: 22245094
[TBL] [Abstract][Full Text] [Related]
18. Targeting intrinsic RIG-I signaling turns melanoma cells into type I interferon-releasing cellular antitumor vaccines.
Bek S; Stritzke F; Wintges A; Nedelko T; Böhmer DFR; Fischer JC; Haas T; Poeck H; Heidegger S
Oncoimmunology; 2019; 8(4):e1570779. PubMed ID: 30906666
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation.
Meng G; Xia M; Xu C; Yuan D; Schnurr M; Wei J
Int J Cancer; 2014 Apr; 134(8):1958-71. PubMed ID: 23921958
[TBL] [Abstract][Full Text] [Related]
20. Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1.
Yang Z; Qi Y; Lai N; Zhang J; Chen Z; Liu M; Zhang W; Luo R; Kang S
J Exp Clin Cancer Res; 2018 Jan; 37(1):1. PubMed ID: 29301578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
